CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 114 enrolled
Drug / intervention
Argatroban +1 moredrug
Likely dose
Argatroban 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01163604
NCT01163604Phase 4Completed
CompareCT.gov

Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting

Jinling Hospital, China·interventional·Posted Jul 16, 2010·Updated Nov 23, 2015

In Brief

A Phase 4 clinical trial evaluating Argatroban and non-argatroban treated group for CVD. Completed, enrolled 114 participants across 1 site.

Detailed Summary

Argatroban is a selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI could potentially prevent reocclusion. But there has no study on large sample of argatroban treated restenosis post cranial stenting. This study will test the safety and efficacy of the argatroban on prevent occlusion and restenosis in patients with intracranial and extracranial artery stenting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCVD
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 16, 2010
Enrollment StartAug 1, 2010
Primary CompletionDec 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.0 years ago

Interventions

Argatrobandrug

Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment

non-argatroban treated groupdrug

Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.